Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 77, Issue 3, 2006, Pages 217-225

  Goto, Naoe ^a   Tsurumi, Hisashi ^a   Takemura, Masao ^a   Hara, Takeshi ^b   Sawada, Michio ^b   Kasahara, Senji ^a   Kanemura, Nobuhiro ^a   Yamada, Toshiki ^a   Shimizu, Masahito ^a   Takahashi, Takeshi ^c   Tomita, Eiichi ^c   Seishima, Mitsuru ^a   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a,d  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Internal Medicine   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; International prognostic index; Prognostic factor; Soluble TNF receptor; Tumor necrosis factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PIRARUBICIN; PREDNISOLONE; TUMOR NECROSIS FACTOR RECEPTOR 2; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SAMPLE SIZE; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SOLUBILITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746811856     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00702.x     Document Type: Article

References (37)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
2. RUCO LP, POMPONI D, PIGOTT R, et al. Cytokine production (IL-1α, IL-1β, and TNFα) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadentis, Hodgkin's disease, and in non-Hodgkin's lymphomas. Am J Pathol 1990;17:1163-1171.
3. DIGEL W, STEFANIC M, SCHÖNIGER W, BUCK C, RAGHAVACHAR A, FRICKHOFEN N, HEIMPEL H, PORZSOLT F. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989;73:1242-1246.
4. TRENTIN L, ZAMBELLO R, AGOSTINI C, SIVIERO F, ADAMI F, MARCOLONGO R, RAIMONDI R, CHISESI T, PIZZOLO G, SEMENZATO G. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 1993;81:752-758.
5. THOMMESEN L, LAEGREID A. Distinct differences between TNF receptor 1- and TNF receptor 2-mediated activation of NFkappaB. J Biochem Mol Biol 2005;38:281-289.
6. ADERKA D, ENGELMANN H, MAOR Y, BRAKEBUSCH C, WALLACH D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
7. ADERKA D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-240.
8. NOPHAR Y, KEMPER O, BRAKEBUSCH C, ENGELMANN H, ZWANG R, ADERKA D, HOLTMANN H, WALLACH D. Soluble forms of tumor necrosis factor receptors (sTNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. The EMBO J 1990;9:3269-3278.
9. WARZOCHA K, SALLES G, BIENVENU J, BASTION Y, DUMONTET C, RENARD N, NEIDHARDT-BERARD EM, COIFFIER B. Tumor necosis factor ligand-receptor sysem can predict treatment outcome in lymphoma patients. J Clin Oncol 1997;15:499-508.
10. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
11. JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. World Health Organization Classification of Tumors, Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001:109-236.
12. CARBONE PP, KAPLAN HS, MUSSHOFF K, SMITHERS DW, TUBIANA M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
13. TSURUMI H, YAMADA T, SAWADA M, et al. Biweekly CHOP or biweekly THP-COP regimens in the treatment of aggressive non-Hodgkin's lymphoma - a comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107-113.
14. TAKAGI T, OGURO M. (2″-R)-4′-o-Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 1987;20:151-154.
15. MILLER AA, SALEWSKI E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261-268.
16. KITAMURA K, TAKAKU F. Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990;13:S15-S19.
17. SAWADA M, TSURUMI H, YAMADA T, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002;68:354-361.
18. CHESON BD, HORNING SJ, COIFFIER B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.
19. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. COX DR. Regression models and life-tables (with discussions). J Roy Stat Soc (Ser B) 1972;34:187-220.
21. HAIOUN C, LEPAGE E, GISSELBRECHT C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997;15:1131-1137.
22. SHIPP MA, ABELOFF MD, ANTMAN KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: Report of the July. J Clin Oncol 1999;17:423-429.
23. ICHIKAWA A, KINOSHITA T, WATANABE T, KATO H, NAGAI H, TSUSHITA K, SAITO H, HOTTA T. Mutation of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529-534.
24. NIITSU N, OKABE-KADO J, OKAMOTO M, TAKAGI T, YOSHIDA T, AOKI S, HIRANO M, HONMA Y. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001;97:1202-1210.
25. HARA T, TSURUMI H, TAKEMURA M, GOTO H, YAMADA T, SAWADA M, TAKAHASHI T, MORIWAKI H. Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 2000;64:257-261.
26. ALIZADEH AA, EISEN MB, DAVIS RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
27. CASEY LC, BALK RA, BONE RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Int Med 1993;119:771-778.
28. HOLLER E, KOLB HA, MÖLLER A, et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990;75:1011-1016.
29. SALLES G, BIENVENU J, BASION Y, BARBIER Y, DOCHE C, WARZOCHA K, GUTOWSKI MC, RIEUX C, COFFIER B. Elevated circulating levels of TNF-a and its p55 soluble receptor and associated with an adverse prognosis in lymphoma patients. Brit J Haematol 1996;93:352-359.
30. HERVE P, FLESCH M, TIMBERGHIEN P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus disease. Blood 1992;79:3362-3368.
31. HAAK-FRENDCHO M, MARSTERS SA, MORDENTI J, BRADY S, GILLET NA, CHEN SA, ASHKENAZI A. Inhibition of TNF by a TNF receptor immunoadhesion comparison to an anti-TNF monoclonal antibody. J Immunol 1994;152:1347-1353.
32. OR R, KALINKOVICH A, NAGLER A, WEISMAN Z, NAPARSTEK E, WEISS L, HAHN T. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone transplantation-related complications. Cytokines Mol Ther 1996;2:243-250.
33. METKAR SS, NARESH KN, MANMA PP, SRINIVAS V, ADVANNI SH, NADKARNI JJ. Circulating levels of TNFα and TNF receptor superfamily members in lymphoid neoplasia. Am J Hematol 2000;65:105-110.
34. VASSALLI P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
35. OR R, MATZNER Y, KONJIN MA. Serum ferritin in patients undergoing bone marrow transplantation. Cancer 1987;60:1127-1131.
36. SYMINGTON FW, PEPE MS, CHEN AB, DELIGANIS A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation 1990;50:518-521.
37. GIBBONS DL, ROWE M, COPE AP, FELDMANN M, BRENNAN FM. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol 1994;24:1879-1885.